{
    "clinical_study": {
        "@rank": "137756", 
        "arm_group": [
            {
                "arm_group_label": "vitamin D + fish oil", 
                "arm_group_type": "Active Comparator", 
                "description": "vitamin D3 + Omacor"
            }, 
            {
                "arm_group_label": "vitamin D + fish oil placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "vitamin D3 + fish oil placebo"
            }, 
            {
                "arm_group_label": "vitamin D placebo + fish oil", 
                "arm_group_type": "Active Comparator", 
                "description": "vitamin D placebo + Omacor"
            }, 
            {
                "arm_group_label": "vitamin D placebo + fish oil placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "vitamin D placebo + fish oil placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is an ongoing randomized clinical\n      trial in 25,875 U.S. men and women investigating whether taking daily dietary supplements of\n      vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor\u00ae fish oil, 1 gram) reduces the risk of\n      developing cancer, heart disease, and stroke in people who do not have a prior history of\n      these illnesses. This ancillary study is being conducted among participants in VITAL and\n      will examine whether vitamin D or omega-3 fatty acids affect risk of infection and plasma\n      hCAP18 levels."
        }, 
        "brief_title": "Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)", 
        "completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Infections", 
            "Human Cathelicidin Antimicrobial Peptide (hCAP-18)"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Communicable Diseases", 
                "Infection"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Participants in VITAL (NCT 01169259) are eligible to participate in this ancillary study.\n        Please see NCT 01169259 for lists of inclusion and exclusion criteria."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "25875", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01758081", 
            "org_study_id": "AI093723"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "vitamin D + fish oil", 
                    "vitamin D + fish oil placebo"
                ], 
                "description": "Vitamin D3 (cholecalciferol), 2000 IU per day", 
                "intervention_name": "vitamin D3", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "vitamin D + fish oil", 
                    "vitamin D placebo + fish oil"
                ], 
                "description": "Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])", 
                "intervention_name": "omega-3 fatty acids (fish oil)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "vitamin D placebo + fish oil", 
                    "vitamin D placebo + fish oil placebo"
                ], 
                "intervention_name": "Vitamin D3 placebo", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "vitamin D + fish oil placebo", 
                    "vitamin D placebo + fish oil placebo"
                ], 
                "intervention_name": "fish oil placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cholecalciferol", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 7, 2014", 
        "link": {
            "description": "VITAL study website", 
            "url": "http://www.vitalstudy.org/"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02215"
                }, 
                "name": "Brigham and Women's Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "upper respiratory infection", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "measure": "hCAP-18", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01758081"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "Carlos A. Camargo", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "lower respiratory infection", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "urinary tract infection", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "cellulitis", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "antimicrobial-treated infection", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "infection-related hospitalizations", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}